References
- Armstrong AW, Mehta MD, Schupp CW, et al. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):1–10. doi: 10.1001/jamadermatol.2021.2007.
- Michalek IM, Loring B, John SM. Global report on psoriasis. Geneva, Switzerland: World Health Organization; 2016.
- Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072. doi: 10.1016/j.jaad.2018.11.057.
- Helmick CG, Lee-Han H, Hirsch SC, et al. Prevalence of psoriasis among adults in the U.S.: 2003–2006 and 2009–2010 National Health and Nutrition Examination Surveys. Am J Prev Med. 2014;47(1):37–45. doi: 10.1016/j.amepre.2014.02.012.
- Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10. doi: 10.1007/s00403-010-1080-1.
- Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(Suppl. 2):ii65–ii68. doi: 10.1136/ard.2004.031237.
- Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151(6):651–658. doi: 10.1001/jamadermatol.2014.3593.
- Gelfand JM, Feldman SR, Stern RS, et al. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004;51(5):704–708. doi: 10.1016/j.jaad.2004.04.014.
- Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445–1486. doi: 10.1016/j.jaad.2020.02.044.
- Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258–269. doi: 10.1001/jamadermatol.2019.4029.
- Institute for Clinical Economic Review. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value. Boston (MA): Institute for Clinical Economic Review; 2018.
- Sotyktu [package insert]; 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214958s000lbl.pdf
- Catlett IM, Hu Y, Gao L, et al. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2022;149(6):2010–2020.e8. doi: 10.1016/j.jaci.2021.11.001.
- Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29–39.
- Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program for evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88(1):40–51.
- Armstrong AW, Park SH, Patel V, et al. Matching-adjusted indirect comparison of the long-term efficacy of deucravacitinib versus adalimumab for moderate to severe plaque psoriasis. Dermatol Ther. 2023;13(11):2589–2603. doi: 10.1007/s13555-023-00977-1.
- Armstrong AW, Feldman SR, Korman NJ, et al. Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis. J Dermatol Treat. 2017;28(3):200–205.
- Warren RB, Gooderham M, Burge R, et al. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: results from a network meta-analysis. J Am Acad Dermatol. 2020;82(5):1138–1149. doi: 10.1016/j.jaad.2019.12.038.
- Symphony Health Anonymized Patient Level Data (APLD). Based on a 3 month rolling average for the total population. Dublin (Ireland): Icon; 2022.
- Armstrong AW, Warren RB, Zhong Y, et al. Short-, mid-, and long-term efficacy of deucravacitinib versus biologics and nonbiologics for plaque psoriasis: a network meta-analysis. Dermatol Ther. 2023;13(11):2839–2857. doi: 10.1007/s13555-023-01034-7.
- U.S. Bureau of Labor Statistics. CPI for all urban consumers. Medical care in U.S. city average, all urban consumers, seasonally adjusted; 2021 [cited 2021 Apr]. Available from: https://data.bls.gov/
- IBM Watson. Merative™ Micromedex®. RED BOOK®; 2023 [cited 2023 Feb]. Available from: https://www.micromedexsolutions.com/micromedex2/librarian/
- Skyrizi [package insert]; 2019 [cited 2022 Nov]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761105s000lbl.pdf
- Humira [package insert]; 2018 [cited 2022 Nov]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125057s406lbl.pdf
- Siliq [package insert]; 2017 [cited 2022 Nov]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761032lbl.pdf
- Tremfya [package insert]; 2017 [cited 2022 Nov]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761061s000lbl.pdf
- Enbrel [package insert]; 2021 [cited 2022 Nov]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103795s5582lbl.pdf
- Taltz [package insert]; 2016 [cited 2022 Nov]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125521s000lbl.pdf
- Ilumya [package insert]; 2018 [cited 2022 Nov]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf
- Stelara [package insert]; 2016 [cited 2022 Nov]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761044lbl.pdf
- Carrico J, Zhao Y, Jia X, et al. The budget impact of introducing tildrakizumab to a United States health plan for managing moderate-to-severe plaque psoriasis. Pharmacoecon Open. 2020;4(4):669–677. doi: 10.1007/s41669-020-00208-9.
- Practice Management Information Corporation (PMIC). Medical fees 2021 eBook. Los Angeles (CA): Practice Management Information Corporation; 2020. Available from: https://www.pmiconline.com/
- Feldman SR, Zhang J, Martinez DJ, et al. Real-world biologic and apremilast treatment patterns and healthcare costs in moderate-to-severe plaque psoriasis. Dermatol Online J. 2021;27(1):2.
- Blauvelt A, Burge R, Malatestinic W, et al. Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review. J Manag Care Spec Pharm. 2021;27(1):84–94. doi: 10.18553/jmcp.2021.27.1.084.
- Teeple A, Fitzgerald T. Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis. J Dermatol Treat. 2022;33(1):518–524.
- Teeple A, Muser E. Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis. J Med Econ. 2019;22(12):1268–1273. doi: 10.1080/13696998.2019.1632204.
- Al Sawah S, Foster SA, Burge R, et al. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis. J Med Econ. 2017;20(12):1224–1230. doi: 10.1080/13696998.2017.1362413.
- Feldman SR, Foster SA, Zhu B, et al. Cost per additional responder associated with ixekizumab and etanercept in the treatment of moderate-to-severe psoriasis. J Drugs Dermatol. 2017;16(12):1246–1252.
- Mattingly TJ, Levy JF, Slejko JF, et al. Estimating drug costs: how do manufacturer net prices compare with other common US price references? Pharmacoeconomics. 2018;36(9):1093–1099. doi: 10.1007/s40273-018-0667-9.